상세 보기
Moderate-Intensity Statins Plus Ezetimibe vs. High-Intensity Statins After Coronary Revascularization: A Cohort Study
- Kim, Juwon;
- Kang, Dan Bee;
- Park, Hyejeong;
- Kang, Minwoong;
- Choi, Ki Hong;
- ... Park, Taek Kyu;
- ... Lee, Joo Myung;
- ... Yang, Jeong Hoon;
- ... Song, Young Bin;
- ... Choi, Jin-Ho;
- ... Choi, Seung-Hyuk;
- ... Gwon, Hyeon-Cheol;
- ... Cho, Juhee;
- ... Hahn, Joo-Yong;
- 외 1명
WEB OF SCIENCE
8SCOPUS
10초록
Purpose Whether moderate-intensity statins plus ezetimibe could be an alternative to high-intensity statins in patients with atherosclerotic cardiovascular disease is unclear. We compared the risk of adverse cardiovascular events in patients receiving moderate-intensity statins plus ezetimibe vs. high-intensity statins after a coronary revascularization procedure using data from a large cohort study. Method Population-based cohort study using nationwide medical insurance data from Korea. Study participants (n = 20,070) underwent percutaneous coronary intervention or coronary artery bypass graft surgery between January 1, 2015, and December 31, 2016, and received moderate-intensity statins (atorvastatin 10-20 mg or rosuvastatin 5-10 mg) plus ezetimibe (n = 922) or high-intensity statins (atorvastatin 40-80 mg or rosuvastatin 20 mg; n = 19,148). The primary outcome was a composite of cardiovascular mortality, hospitalization for myocardial infarction (MI), hospitalization for stroke, or revascularization. Results At 12 months, the incidence rates of the primary outcome were 138.0 vs. 154.0 per 1000 person-years in the moderate-intensity stains plus ezetimibe and the high-intensity statins group, respectively. The fully adjusted hazard ratio [HR] for the primary outcome was 1.11 (95% confidence interval [CI] 0.86-1.42; p = 0.43). The multivariable-adjusted HR for a composite of cardiovascular mortality, hospitalization for MI, or hospitalization for stroke was 1.05 (95% CI 0.74-1.47; p = 0.80). During follow-up, the proportion of patients maintaining their initial lipid-lowering therapy was significantly higher in the moderate-intensity statins plus ezetimibe group than in the high-intensity statins group. Conclusions Patients undergoing a coronary revascularization procedure who received moderate-intensity statins plus ezetimibe showed similar rates of major adverse cardiovascular events as patients who received high-intensity statins.
키워드
- 제목
- Moderate-Intensity Statins Plus Ezetimibe vs. High-Intensity Statins After Coronary Revascularization: A Cohort Study
- 저자
- Kim, Juwon; Kang, Dan Bee; Park, Hyejeong; Kang, Minwoong; Choi, Ki Hong; Park, Taek Kyu; Lee, Joo Myung; Yang, Jeong Hoon; Song, Young Bin; Choi, Jin-Ho; Choi, Seung-Hyuk; Gwon, Hyeon-Cheol; Guallar, Eliseo; Cho, Juhee; Hahn, Joo-Yong
- 발행일
- 2023-02
- 유형
- Article
- 권
- 37
- 호
- 1
- 페이지
- 141 ~ 150
- 언어
- ENG
- 출판사
- Kluwer Academic Publishers
- 발행국가
- 네덜란드
- 분량
- 10 페이지
- ISSN
- E 1573-7241
P 0920-3206